XML 32 R19.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Stock Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Share-based Payment Arrangement [Abstract] |
Stock Based Compensation | Stock Based Compensation On May 13, 2021, the Company's shareholders approved the 2021 Long Term Equity Incentive Plan (the “2021 Plan”) that replaced the 2006 Long Term Equity Incentive Plan (the “2006 Plan”) approved in May 2006 and amended in May 2015. The 2021 Plan allows for grants to employees, officers, non-employee directors, consultants, independent contractors and advisors of non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards (“stock awards”) up to an aggregate of 714,686 awards. Awards can be granted under the 2021 Plan through the earlier of May 13, 2031, or the date the maximum number of available awards under the 2021 Plan have been granted. No new awards may be granted from the 2006 Plan. Awards under the 2021 Plan vest over one to three years and shares previously awarded and currently unvested under the 2006 Plan vest over three years. Shares granted under both the 2006 and 2021 Plans vest upon the date of a participant’s death, disability or change in control. The Company follows the provisions of FASB ASC 718 requiring that compensation cost relating to share-based payment transactions be recognized in the financial statements. The cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity award). Restricted Stock The Company grants shares of its common stock to certain directors and officers in the form of unvested stock (“Restricted Stock”). These awards are measured at the fair value of Core Molding Technologies’ common stock on the date of issuance and recognized ratably as compensation expense over the applicable vesting period. The following summarizes the status of Restricted Stock and changes during the years ended December 31:
| 2021 |  | 2020 |  | 2019
| Number of Shares |  | Wtd. Avg. Grant Date Fair Value |  | Number of Shares |  | Wtd. Avg. Grant Date Fair Value |  | Number of Shares |  | Wtd. Avg. Grant Date Fair Value
Unvested - beginning of year | 507,835 |  | $ | 6.35 |  |  | 343,919 |  | $ | 9.37 |  |  | 349,885 |  | $ | 10.62 |
Granted | 250,635 |  | 13.74 |  |  | 292,886 |  | 4.70 |  |  | 135,268 |  | 7.65 |
Vested | (262,461) |  | 6.89 |  |  | (107,145) |  | 10.21 |  |  | (117,828) |  | 13.81 |
Forfeited | (36,589) |  | 7.66 |  |  | (21,825) |  | 9.86 |  |  | (23,406) |  | 15.02 |
Unvested - end of year | 459,420 |  | $ | 9.79 |  |  | 507,835 |  | $ | 6.35 |  |  | 343,919 |  | $ | 9.37 |
At December 31, 2021 and 2020, there was $3,029,000 and $1,614,000, respectively, of total unrecognized compensation expense. That cost is expected to be recognized over the weighted-average period of 2.1 years. Total compensation expense related to restricted stock grants for the years ended December 31, 2021, 2020 and 2019 was $1,762,000, $1,254,000, and $1,369,000, respectively, and is recorded as selling, general and administrative expense. Tax deficiencies in connection with payment of taxes upon the vesting of restricted stock previously issued to employees for the years ended December 31, 2021, 2020 and 2019 were a tax deficiency of $305,000, $97,000, and $98,000, respectively. During 2021, 2020 and 2019, employees surrendered 7,237, 4,574 and 16,047 shares, respectfully, of the Company's common stock to satisfy income tax withholding obligations in connection with the vesting of restricted stock. Stock Appreciation Rights As part of the Company's 2019 annual grant, Stock Appreciation Rights (SARs) were granted with a grant price of $10. These awards have a contractual term of five years and vest ratably over a period of three years or immediately vest if the recipient is over 65 years of age. These awards are valued using the Black-Scholes option pricing model, and are amortized ratably as compensation expense over a three year period. A summary of the Company's stock appreciation rights activity for the years ended December 31, is as follows:
| 2021 |  | 2020 |  | 2019
| Number of Shares |  | Wtd. Avg. Grant Date Fair Value |  | Number of Shares |  | Wtd. Avg. Grant Date Fair Value |  | Number of Shares |  | Wtd. Avg. Grant Date Fair Value
Outstanding - beginning of year | 180,925 |  |  | $ | 2.57 |  |  | 222,112 |  |  | $ | 2.57 |  |  | — |  |  | $ | — |
Granted | — |  |  | — |  |  | — |  |  | — |  |  | 226,021 |  |  | 2.57 |
Exercised | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Forfeited | (3,909) |  |  | 2.57 |  |  | (41,187) |  |  | 2.57 |  |  | (3,909) |  |  | 2.57 |
Outstanding - end of year | 177,016 |  |  | $ | 2.57 |  |  | 180,925 |  |  | $ | 2.57 |  |  | 222,112 |  |  | $ | 2.57 |
Exercisable - end of year | 124,801 |  |  | $ | 2.57 |  |  | 73,888 |  |  | $ | 2.57 |  |  | 29,028 |  |  | $ | 2.57 |
The average remaining contractual term for SARs outstanding at December 31, 2021 is 2.3 years, with $0 aggregate intrinsic value. At December 31, 2021 and 2020, there was $45,000 and $179,000, respectively, of total unrecognized compensation expense related to SARs. That cost is expected to be recognized over the weighted-average period of 0.3 years. Total compensation cost related to SARs for the years ended December 31, 2021, 2020 and 2019 was $127,000, $101,000 and $185,000 respectively, all of which was recorded to selling, general and administrative expense.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration